Drug Trial Radar · NCT01760109
Piperacillin Sodium and Sulbactam Sodium for Injection(2:1) for Treatment of Respiratory and Urinary System Infection
Last checked: Nov 20, 2026Latest source record: Jul 8, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,000
Actual
Start
Jul 2011
Primary completion
Jun 2016
Study completion Jun 2016
Sponsor
- Lead sponsor
- Xiangbei Welman Pharmaceutical Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Jan 3, 2013
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In the proposed study, the investigators plan to evaluate the efficacy and safety of Piperacillin Sodium and Sulbactam Sodium for Injection(2:1) for the treatment of respiratory and urinary tract acute bacterial infection.
Conditions
- Respiratory Tract Infections
- Urinary Tract Infections
Interventions
Piperacillin Sodium and Sulbactam SodiumDrug
1.5-3.0g,iv,bid 7-14 days serious infections 6.0-12.0g,iv,tid for 7-14 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- The rate of bacterial clearanceTime frame: two years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Chongqing Red Cross hospital
Chongqing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.